![]() Furthermore, generic drugs offer an affordable alternative for managing chronic diseases. As the population ages and the prevalence of chronic diseases increases, the need for cost-effective medication options becomes crucial. Chronic diseases, such as diabetes, cardiovascular conditions, and respiratory disorders, are prevalent and require long-term medication use. The growing demand for chronic disease management is favorably impacting the market. Growing demand for chronic disease management Additionally, the expiration of patents for several blockbuster drugs creates growth opportunities for generic manufacturers. Besides, the aging population in the United States requires a larger volume of medications. Moreover, numerous government initiatives encourage the use of generic drugs by providing incentives and lower reimbursement rates for generic prescriptions, thereby creating a positive outlook for the market. ![]() Apart from this, with the rising cost of healthcare, including prescription medications, payers and healthcare providers seek to promote the use of generic drugs to contain expenses, thus catalyzing the market. ![]() In line with this, the increasing number of expired patents is significantly contributing to the market. The market in the United States is majorly driven by the easy availability and affordability of the product. ![]() They play a crucial role in providing cost-effective alternatives to brand-name drugs, promoting competition in the pharmaceutical market, and enhancing the overall efficiency of healthcare systems in the United States. Generic drugs offer several advantages, including lower cost, increased accessibility, and greater affordability, making healthcare more affordable and accessible to a wider population. These medications contain the same active ingredients as their brand-name counterparts and undergo rigorous testing by regulatory authorities to ensure their quality, safety, and effectiveness. It is produced and marketed after the patent protection of the original brand-name drug expires. Two Affiliate Companies Joined Endo International plc BankruptcyĮarnings Flash (ENDPQ) ENDO INTERNATIONAL Reports Q1 Adjusted EPS $0.A generic drug is a pharmaceutical product that is bioequivalent to a brand-name drug in terms of dosage, strength, safety, efficacy, route of administration, and intended use. Premier Forms Pitocin Supply Partnership With Endo InternationalĮndo International plc Launches First Generic Version of Noxafil® (posaconazole) InjectionĮndo International plc Announces Approval of XCOPRI (Cenobam Tablets) in CanadaĮndo International plc Announces First Patient Enrolled in Registry of Dupuytren's ContractureĮndo International plc Launches Dexlansoprazole Capsules, Generic Version of DexilantĮndo International plc Launches PREVDUO (Neostigmine Mylsulfate and Glycopyrrolate Injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe Second Motion for Exclusivity Period Extension Approved For Endo International plcīankrupt Endo says US government objections imperil $600 million in opioid settlements Tranche Update on Endo International plc (OTCPK:ENDP.Q)'s Equity Buyback Plan announced on April 30, 2015.Įarnings Flash (ENDP) ENDO INTERNATIONAL Posts Q2 Revenue $547MĮarnings Flash (ENDP) ENDO INTERNATIONAL Reports Q2 EPS $0.98Įndo International plc Revises Earnings Guidance for the Year 2023Įndo International plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |